Mitochondrial DNA sequencing demonstrates clonality of peritoneal implants of borderline ovarian tumors

Table 1 Cases and histopathology

Patients	Age at diagnosis	Surgery	Histology	Staging (FIGO 2014)	Implant type	Implant localization	DFS	OS
B1	35	FS	Serous BOT	IIB	Non invasive	Pelvic peritoneum	48	74
B2	44	CS	Serous BOT	IIC3	Non invasive	Pelvic peritoneum	34	34
B3	30	FS	Serous BOT with intraepithelial carcinoma	IIIA	Non invasive	Pelvic peritoneum and omentum	31	31
B4	81	CS	Serous BOT	IIB	Non invasive	Pelvic peritoneum	120	120
B5	23	FS	Serous BOT with intraepithelial carcinoma	IIC3	Invasive	Pelvic peritoneum	30	67
B6	32	FS	Serous BOT	IIC3	Non invasive	Pelvic peritoneum	7	68
B7	34	FS	Serous BOT	IIIA	Non invasive	Pelvic peritoneum, pararectal peritoneum	13	128
B8	63	CS	Serous BOT	IIIA	Non invasive	Pelvic peritoneum, omentum and right diaphragmatic peritoneum	16	16

Age, surgery, histology and FIGO stage of borderline ovarian tumors, implants type and localization, months from treatment until first relapse and months from diagnosis to last follow up are shown
Abbreviations: FS Fertility Sparing treatment, CS Complete Staging, BOT Borderline Ovarian Tumor, DFS Disease Free Survival, OS Overall Survival

ISSN: 1476-4598